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Inter-a-trypsin inhibitor heavy-chain proteins bind to the
protease inhibitor bikunin and to hyaluronan, stabilizes
extracellular matrix in various tissues, and also inhibits
calcium oxalate crystallization in vitro. In both normal and
stone-forming patients, we found heavy chain 3 and
hyaluronan in the interstitial matrix of the kidney.
Osteopontin was found in the collecting duct, thin loop of
Henle, and urothelial cells. In stone formers, heavy chain 3
was also present in collecting duct, thin loop, and interstitial
cells. Heavy chain 3 and osteopontin colocalized in plaque
matrix and urothelial cells. Within individual plaque
spherules, heavy chain 3 was found in the matrix layer while
osteopontin was located along the crystal–matrix interface.
Bikunin was present only in the collecting duct apical
membranes and the loop cell cytoplasm of stone formers
colocalizing with osteopontin and heavy chain 3. Widespread
heavy chain 3 was only present in stone formers, whereas
osteopontin was similarly expressed in normal and
stone-forming subjects except for its localization in plaques
of the stone formers. This is consistent with studies linking
inter-a-trypsin inhibitor components to human stone disease,
although their role is still unclear. Heavy chain 3 may also
play a role in stabilizing hyaluronan in the renal interstitial
matrix.
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The inter-a-inhibitor (IaI) family includes a group of related
proteins that have in common one or more heavy chains
attached to bikunin.1 Of these, the inter-a-trypsin inhibitor
has been linked to human calcium oxalate (CaOx) nephro-
lithiasis because it is present in the CaOx stone matrix, and is
an effective inhibitor of CaOx crystallization.2–4 IaI is a
glycoprotein in which two heavy chains (H1 and H2) are
covalently linked to bikunin via a chondroitin sulfate bridge.1
Bikunin is a protease inhibitor, can be a component of CaOx
stone matrix,2 and inhibits CaOx crystallization.5–7 Using
direct measurements of crystal size, intact IaI was more
inhibitory for crystal growth on a molar basis than any of its
constituents; H1 and bikunin had sequentially less activity.8
By contrast, using a seeded crystal growth assay, neither IaI
nor H1 was effective, whereas bikunin was;4 the same was
found using direct measurements of crystal size or a
nucleation inhibition assay. Despite these variable results,
one concludes that at least some portions of IaI and perhaps
the whole molecule are inhibitory in urine.
IaI family proteins may be increased in urine of stone
formers. In a study of male and female relatives of calcium
stone formers, we have found an increase of high-molecular-
weight (450 kDa) immunoreactive IaI components in the
urine of those who formed stones vs those who did not.9
However, the conditions used could not identify the nature of
the heavy chains that were present. In another study, IaI and
the dimer of bikunin and H1 or H2 were found more often in
urine in stone-forming males than in normal males;10 the
dimer of bikunin and H3 was not identified, although H3
monomers were detected. Another study confirmed increased
urine IaI in stone formers vs normals of both sexes.11
Pre-a trypsin inhibitor (PaI) is a related protein that
differs from IaI in that PaI contains bikunin bound to heavy
chain 3 (H3). PaI also appears to have links to experimental
stone disease. In rats with ethylene glycol-induced renal
crystallization, tissue abundance of IaI, bikunin, and H1 and
H3 were increased in most tubule cells, especially in those
tubules that contained crystals,12 particularly proximal
tubules and collecting ducts. Crystals themselves were heavily
stained. In another study,13 after ethylene glycol, urine
IaI and PaI rose with time in rats; kidney bikunin mRNA
rose as well. Immunostaining for IaI localized mainly in
proximal and distal tubules and luminal contents. In other
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experiments, expression of bikunin mRNA by cultured renal
epithelial cells (Madin–Darby canine kidney cells) was
increased on exposure to oxalate ion but not by CaOx
crystals.14
Hyaluronan is a glycosaminoglycan that is found in renal
medullary interstitium.15 It is believed to play a role in water
handling by affecting the physicochemical characteristics of
the papillary interstitial matrix.16 In some tissues, hyaluronan
is known to bind heavy-chain proteins, including H3, which
are believed to stabilize the matrix by inhibiting degradation
of hyaluronan,17 whether this occurs in renal interstitial
matrix is unknown.
Our own work has led us to explore further the
relationship of the IaI family and hyaluronan to calcium
stone disease. In idiopathic CaOx stone formers (ICSFs), who
have no systemic cause for stones apart from genetic
(idiopathic) hypercalciuria, we have found papillary inter-
stitial deposits of apatite crystal (Randall’s plaque) as a sole
histopathological lesion.18 Associated with plaque, we found
osteopontin, particularly on the surfaces of the apatite within
the microspherulites that compose plaque.19 Given that
bikunin and IaI can affect calcium crystallization, that urine
levels of IaI mark human stone formers, and that both
appear to increase in a form of experimental nephrolithiasis
with intraluminal CaOx crystals, we have asked if increased
levels of members of the IaI family are present in renal tissues
from ICSFs. In addition, it has been proposed that
hyaluronan may play a role in the formation of interstitial
calcium apatite plaque because of its ability to bind calcium,
and that hyaluronan may be increased in plaque.20 In
undertaking this work, we recognized that mechanisms
producing stones in ICSFs may well differ radically from
those operative in ethylene glycol-induced stones in that the
crystals in ICSF kidneys are interstitial and composed of
apatite rather than being intraluminal and composed of
CaOx. Moreover, given that H1 and H3 appeared selectively
increased in experimental stone disease, we have quantified
all three heavy chains separately, along with bikunin,
osteopontin, and hyaluronan.
RESULTS
Patients
We studied seven ICSFs, all of whom had formed at least two
CaOx stones, and none of whom had systemic disorders,
such as primary hyperparathyroidism, renal tubular acidosis,
hyperthyroidism, and sarcoidosis, and no stones contained
uric acid, cystine, struvite, or more than 50% calcium
phosphate. Six of these patients were part of a larger group of
ICSFs described previously,21 and one new patient has been
added. Three normal (N) subjects were also studied as
before.18 Table 1 shows pertinent clinical and laboratory data
for these subjects.
Histologic data
For simplicity of presentation, we comment here that all of
the subsequent findings were exactly the same in tissues from
the seven ICSFs we studied; hence, we do not present either
individual patient data or statistical summaries. Likewise, we
found no difference between male and female ICSFs.
Similarly, all the normals had consistent findings.
Plaque is found in papilla of ICSFs but not normals
As we have already established,18 Yasue-positive interstitial
apatite deposits are present in the interstitium of ICSF
(Figure 1b) but not in normal (Figure 1a) renal papillum.
Normal papilla contain H3, but not bikunin, H1, or H2
Bikunin staining is negative in normal papillary tissue
(Figure 2a and Table 2), as is staining for H1 and H2 by
both light microscopy and transmission electron microscopy
Table 1 | Patient’s characteristics
Demographic information Lab measurements
Case Sex
Age at
biopsy
Age at
first stone
Total
stones ESWL PNL
Total
proc Scr Ca/Cr Vol Ox SS CaOx
Stone formers
1 F 23 22 3 1/0 2/1 3/1 0.8 158 0.92 27 11.54
2 M 41 41 2 0 1/1 2/1 1 97 1.68 32 6.18
3 M 29 18 3 0 1/1 1/1 0.9 176 0.83 14 6.73
4 F 46 45 1 0 1/1 1/1 0.7 225 1.70 65 16.45
5 M 58 42 2 0 3/2 3/2 1 164 1.90 60 11.30
6 M 74 45 7 2/2 1/1 4/4 0.8 219 1.70 45 10.14
7 M 53 17 2 0 1/1 1/1 1.2 162 2.88 37 3.55
Normal subjects
1 F 67 — — — — 1/1 0.8 123 2.42 46 4.84
2 F 40 — — — — 1/1 0.8 64 0.57 17 9.86
3 M 74 — — — — 1/1 1.2 33 1.41 56 3.43
Ca/Cr, urine calcium to creatinine ratio (mg g1); ESWL, extracorporeal shock wave lithotripsy; F, female; M, male; Ox, oxalate (mg d1); PNL, percutaneous nephrolithotomy;
Scr, serum creatinine (mg dl1); SS CaOx, relative supersaturation with respect to calcium oxalate; Total proc, total number of stone procedures; Vol, volume (l d1).
ESWL, PNL, and total procedures are reported as total/number on side of biopsy.
Lab measurements: means of two 24-h urine collections, except for Scr.
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(TEM) (data not shown). By contrast, H3 is present in the
papillary interstitium (Figure 2b) although with light
immunostaining compared with negative control (Figure
2c). TEM immunolocalization reveals H3 only on the type 1
collagen bundles (Figure 2d) of the interstitium.
Bikunin is detectable in the papillary tissue of ICSF and
colocalizes with osteopontin
In contrast to N, bikunin is present in ICSFs, restricted to the
inner medullary collecting duct (IMCD), particularly the
apical cell cytoplasm (Figure 3a) and, using TEM immuno-
localization, to the cells of thin loops of Henle (Figure 3b and
Table 2). H1 and H2 cannot be detected in the tissue of ICSF by
light microscopy or TEM (Figure 3c). In a set of serial sections,
bikunin (Figure 4a) and osteopontin (Figure 4b) both are found
in IMCD apical cell cytoplasm and in cells of the loops of Henle.
These two molecules colocalize (Figure 4c and Table 2) as
shown by the distinct color shift signal from red and greento
orange, respectively. As we have shown elsewhere,19 osteopontin
readily stains regions of plaque (Figure 4b and c), but bikunin is
not present in plaque (Figure 4a and c).
H3 abundance is increased in the papillary tissue of ICSF
Compared to N (Figure 2b), whose papillary tissue displays
faint but definite staining for H3, papillary tissue of ICSFs
contain abundant H3, particularly concentrated in regions of
plaque (Figure 5a and b). At higher magnifications, staining is
present in the basement membranes of loops of Henle and in
the surrounding plaque and interstitial space (Figure 5c–f). In
addition, diffuse staining is present in the cytoplasm of IMCD
and loop of Henle cells, as well as in urothelial cells (Figure 5e
and f). Using TEM immunostaining, H3 is specifically localized
to the matrix of plaque (Figure 6a). Within individual plaque
microspherules (Figure 6b), H3 is within the matrix layers as
opposed to specific association with the mineral deposits
themselves. Using ultracryo freezing techniques that eliminate
potential artifacts from aqueous media, H3 staining is clearly
present on collagen fibers and in the matrix layers of the
microspherules (Figure 6c). In addition, using the same
technique, H3 staining can be localized to the cytoplasm of
papillary interstitial cells (Figure 6d) and to the apical regions of
IMCD cells (Figure 7a) and the cells of the thin loops of Henle
(Figure 7b). These results are summarized in Table 2.
H3 colocalizes with osteopontin in loop cells and plaque
matrix
As expected, H3 is present on the apical surfaces of loop
cells (Figure 8a, white arrow) and in plaque deposits
Table 2 | Summary of immunostaining
Normal Stone former
Site BK H3 OPN HA BK H3 OPN HA
IMCD cells   D  A D D 
Loop cells   D  D D D 
Plaque matrix      + + 
Plaque spherule      M M/I 
Urothelial cells   D   D D 
Interstitial cells      D  ?
Interstitium  +  +  +  +
+, present; , absent; ?, could not be determined; A, apical cystoplasmic staining;
BK, bikunin; H3, heavy chain 3; D, diffuse cytoplasmic staining; HA, hyaluronan;
I, plaque apatite-matrix interface; M, plaque microspherule matrix layer;
OPN, osteopontin.
Shaded cells indicate colocalized proteins.
a b
Figure 1 | Interstitial crystal deposits. Yasue stain reveals interstitial
plaque in an (b) ICSF (arrows) but not in a (a) normal subject. Original
magnification (a and b)  800.
a
c d
b
Figure 2 | Bikunin and heavy-chain localization in normal papilla.
(a) Bikunin staining is negative in normal tissue. (b) H3 staining is
positive in the interstitium (light green, arrows). (c) Without primary
antibody our staining system produces a negative background in
normal tissue. (d) TEM immunogold labeling of H3 (arrow) is positive
on type 1 collagen bundles of the interstitium. Original magnification
(a and b)  800; (c)  700; (d)  25 000.
Kidney International (2007) 72, 1503–1511 1505
AP Evan et al.: Renal bikunin and IaI heavy chain 3 o r i g i n a l a r t i c l e
(arrowheads). Likewise, osteopontin is present in these same
places (Figure 8b). Double staining with both antibodies
reveals color shift (yellow) at the loop and plaque sites
proving colocalization.
H3 but not hyaluronan is increased in and around regions of
plaque
In normal papillary tissue, both hyaluronan (Figure 9a) and
H3 (Figure 9b) are localized in the interstitium. In serial
sections of papillary tissue from ICSFs, plaque is evident with
Yasue stain (Figure 9c, arrowheads), hyaluronan (Figure 9d,
arrow) is present in the interstitium but not in plaque (Figure
9d, arrowheads) and H3 is present in the interstitium (Figure
9e, arrow) and in regions of plaque (Figure 9e, arrowhead).
The intensity of H3 in plaque greatly exceeds than in
interstitium of normals (compare to Figure 9b) or ICSFs
(compare the interstitium with plaque region in Figure 9e).
DISCUSSION
H3 and bikunin abundance are increased in ICSFs, but
hyaluronan is not
Cells. H3 was present in normals but with only weak
staining of the interstitium, not cells. In ICSFs, we found
more abundant H3 than in normals; H3 was localized in
IMCD, loop cells, urothelial cells, and interstitial cells
(Table 2). Osteopontin colocalized with H3 in IMCD cells,
both were diffuse in the cytoplasm; osteopontin colocalized
with bikunin in IMCD cells at the apical cell membrane. In
loop cell cytoplasm, osteopontin, H3, and bikunin all are
present. Bikunin was not present in N.
In humans, IaI contains bikunin, and H1 and H2, but not
H3.1 H1 and H2 were never detected in ICSFs or N,
suggesting that IaI itself is not present in renal papilla.
Bikunin and H3 are components of PaI and in our tissues
they colocalized in the apical membranes of IMCD cells and
in the cytoplasm of loop cells. This suggests that PaI is
present at these two sites in ICSFs, but not in N. We must
conclude that some mechanisms peculiar to stone disease are
increasing either cell H3 and bikunin separately or, more
probably, PaI itself; perhaps our finding of increased urine
heavy-chain components in stone formers9 reflects this
phenomenon.
We cannot determine if our findings reflect increased
production of H3 by ICSF kidney cells, increased uptake from
blood, or both. More research is needed in this area.
a b
c d
Figure 3 | Bikunin localization in ICSF papilla. (a) Bikunin is present
in the apical cytoplasm of IMCD cells (arrowhead). (b) By TEM, bikunin
is localized to the nucleus (arrow) and cytoplasm (double arrow) of
loop of Henle cells. (c) Neither H1 nor H1 and H2 are detected in ICSF.
(d) Without primary antibody our staining system produces a
negative background in ICSF. Original magnification (a)  2000;
(b)  15 000; (c)  300; (d)  700.
a b
c
Figure 4 | Bikunin and OP colocalize in ICSF IMCD and loops.
(a–c) Three serial sections. (a) Bikunin (red color) and (b) osteopontin
(green color) both localize to apical cytoplasm of IMCD (double
arrows), loop cells (arrows), and regions of plaque (arrowheads).
(c) Their colocalization is proven by color shift from red and green
to yellow orange at both sites. Original magnification (a–c)  1000.
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Osteopontin, which colocalized with H3 in IMCD and loop
cells, is made in human collecting duct cells22 and rodent thin
limb and papillary urothelial cells.23 This strengthens the
speculation that H3 could be made there given our findings.
Interstitial cells are not known to produce osteopontin.
Cultured human proximal tubule cells are known to produce
H3 and bikunin,24 and IaI immunoreactivity has been
documented in proximal tubule cells of human kidneys,25
suggesting at least one source for these molecules.
Interstitium and plaque. In ICSFs, H3 abundance in the
interstitium and plaque far exceeded that in N. In plaque, H3
localized to the matrix rather than to the apatite surface, in
contrast to osteopontin that localized, in a previous study, on
the apatite surface and in the matrix.19 We presume H3 plays
some role in crystallization or in its modulation, but these are
speculative comments. Of note, hyaluronan staining was not
increased in plaque.
Comparison to earlier studies. Our findings differ, as one
might expect, from those in rats given ethylene glycol. In the
rats,12,13 both H1 and H3 increased, and the increases were in
cells of proximal tubules, distal tubules, and collecting ducts,
which are sites of CaOx crystal formation in such a model.
The interstitium was negative for H1 and H3, perhaps
because crystals are not deposited there in that model. There
are no earlier human studies.
The role of interstitial H3 is not obvious
Serum levels of PaI are increased in inflammation,26,27 partly
stimulated via interleukin 6. This cytokine has been found
elevated in urine of patients with kidney stones.28 Members
of the IaI family of proteins are well known to bind to
a b
c d f
e
Figure 5 | H3 localization in ICSFs. Abundant staining for H3 is
present in the papillary interstitium at sites of plaque (a: low
magnification panel, arrows; b: high magnification, arrows)
documented by Yasue in serial section (Figure 1b). Higher
magnification micrographs document its presence in basement
membranes and plaque deposits around (c) loops (with inset, arrows)
as well as in surrounding (d) interstitium (arrows). In addition, diffuse
staining is present in cytoplasm of (e) IMCD (arrows) and loop cells as
well as (f) urothelial cells ( arrows). Original magnification (a)  300;
(b)  500; (c)  700; (d)  850; (e and f)  1000.
a b
c d
Figure 6 | H3 localizes to plaque matrix. (a) TEM immunogold
labeling shows diffuse H3 in islands of plaque matrix (arrows). Within
a (b) plaque microspherule (arrows) H3 localizes to the matrix layers
(gray) as opposed to mineral (white). Using ultracryo freezing (c) to
prevent fixation artifacts, H3 remains localized to collagen fibers and
plaque matrix (arrows) and (d) to cytoplasm of interstitial cells
(arrow). Original magnification (a)  15 000; (b)  25 000; (c)
 15 000; (d) 15 000.
a b
Figure 7 | H3 localizes to IMCD and loop cells using ultracryo
freezing. With this precautionary technique, H3 localizes to apical
cytoplasm of (a) IMCD and (b) loop cells (arrows). Original
magnification (a)  25 000; (b)  15 000.
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hyaluronan and such binding stabilizes the extracellular
matrix in a variety of tissues.29 The specific biochemical
events related to extracellular matrix stabilization appears to
be the donation of heavy chains from bikunin to hyal-
uronan.29 In fluid from inflamed joints due to rheumatoid
arthritis, up to 33% of hyaluronan has been found to be
bound to heavy-chain components of IaI including H3.30,31
Although intriguing, these observations do not help us
explain the possible role of PaI in our patients; there are no
other earlier studies we can find to aid in this analysis.
In our particular patients, given the increase of H3, we can
speculate that H3 is donated by PaI to hyaluronan in the
interstitial matrix around plaque. Our findings of hyaluronan
in the regions around plaque, where H3 is abundant, as well
as our finding of hyaluronan and H3 generally in the
interstitium are consistent with this mechanism. Because H3
and hyaluronan are also found in the normal kidney, binding
of H3 to hyaluronan may be part of normal interstitial matrix
production or stabilization. The increase of H3 abundance in
plaque, however, must reflect events particular to stone
formers.
We have thus far found no histological evidence for
inflammation in the renal papillae of ICSFs. Apart from
inflammation, binding of IaI proteins to hyaluronan is well
known as part of tissue remodeling during embryonic
development32 and for stabilization of the cumulus of the
ova33 during oocyte maturation. Hence our findings need not
be taken as definite evidence for tissue injury or inflamma-
tion. Given recent evidence that in disc cartilage TSG-6 and
IaI occur in regions of damage and may suppress inflamma-
tion, our findings may reflect mechanisms that reduce
inflammatory response to plaque.34
Summary
In kidney papillary tissue of ICSF, we have documented
increase of bikunin in IMCD and loop of Henle cells, of H3
in IMCD, loop of Henle, the matrix of Randall’s plaque and
urothelial cells, coexistence of hyaluronan and H3 at normal
levels in the papillary interstitium, and presence of normal
amounts of hyaluronan with increased H3 in the interstitium
around plaque. This suggests a role for PaI in some aspects of
stone disease and accords with findings from animal models
of experimental urolithiasis. This tissue work taken together
with our findings of increased urine high-molecular-weight
a b
c
Figure 8 | H3 and OP colocalize in ICSF. (a–c)Three serial sections.
(a) H3 (red color) and (b) OP (green color) localize to apical surfaces of
loop cells (arrows) and regions of plaque (arrowheads). (c) Double
staining proves colocalization at both sites through color shift from
red and green to yellow orange. Original magnification (a–c)  1000.
a
b c
ed
Figure 9 | Hyaluronan and H3 colocalize in control and ICSF. In
normal papillary tissue, (a) hyaluronan and (b) H3 are localized to the
interstitium (arrow, both panels). In papillary tissue from an ICSF
patient with (c) interstitial plaque (Yasue stain, arrowheads),
hyaluronan stains only the (d) interstitial material (arrow), whereas
(e) H3 stains both the interstitial material (arrows) and sites of
Randall’s plaque (arrowheads). Original magnification
(a and b)  1200; (c–e)  1000.
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IaI components9 strongly supports the idea that these
molecules play some specific and as yet unidentified role in
human stone disease.
MATERIALS AND METHODS
Patients
For this work, we used renal papillary biopsy tissue from six of the
original 15 ICSF patients we have reported previously plus one
new male ICSF patient (totally seven ICSF patients). All formed
CaOx stones and had no systemic cause for stones apart from
hypercalciuria. In addition, we studied tissue from three of the
normal subjects from that same report.18 This human study has
Institutional Review Board approval.
Complete clinical histories were obtained from each subject,
along with reviews of old records to obtain all available stone
analyses. Two 24-h urine samples were collected while patients were
on a random diet for measurement of volume, pH, calcium, oxalate,
citrate, phosphate, uric acid, sodium, potassium, magnesium,
sulfate, and ammonia. From these measurements, we calculated
supersaturations with respect to CaOx, calcium phosphate (as
brushite calcium monohydrogen phosphate), and uric acid using the
EQUIL 2 computer program.35 All samples were measured using
methods detailed elsewhere.36 Blood was drawn in the fasting state
and analyzed for calcium, phosphate, magnesium, sodium, potas-
sium, chloride, creatinine, and carbon dioxide. The blood measure-
ments, most of which are not presented here, served to exclude some
of the systemic disorders noted above.
Light microscopy
General. All biopsy samples used for light microscopy were
fixed in 5% fresh paraformaldehyde as reported previously,18 except
for a biopsy from a new ICSF patient that was fixed in 10% formalin
in 70% ethanol and 5% glacial acetic acid.37 All samples were
dehydrated through graded ethanol concentrations to 100% ethanol
and cleared in xylene before being embedded in Paraplast Xtra
(Fisher Scientific, Itasca, IL, USA). Serial sections were cut at 4 mm
from each sample, placed on charged slides (Fisher Scientific), and
stored at 41C. One section from each set of serial sections was
stained with the Yasue silver substitution method for calcium
histochemistry, whereas the remaining slides were used for
osteopontin, four different protein chains of IaI (bikunin, H1, H1
and H2, and H3), and hyaluronan-binding protein immunolocali-
zation. All paraffin sections were imaged with a Leica DMR
photomicroscope with an RT Slider Spot camera equipped with
fluorescent filters for 40,6-diamidino-2-phenylindole, fluorescein
isothiocyanate, rhodamine, and a triple filter for all three.
Osteopontin immunolocalization. The slides were de-paraffin-
ized and re-hydrated through graded alcohols and blocked for
nonspecific protein binding to the second antibody using 10%
normal serum in 0.1 mol l1 phosphate-buffered saline (PBS) plus
10 mM ammonium chloride and 3% Blotto, at room temperature for
1 h. The osteopontin rabbit polyclonal primary antibody (LF-123), a
gift from Dr Larry Fisher (NIH), was used at a 1:75 dilution and
incubated overnight at room temperature. The secondary antibody
was goat-anti-rabbit-rhodamine IgG (Jackson ImmunoResearch,
West Grove, PA, USA) diluted at 1:150 in 2% normal goat serum/
PBS, which was incubated on the slide at room temperature for
1 h. The slides were then rinsed three times in PBS, once in
double-distilled water, cover slipped with Vectashield mounting
medium for fluorescence with 40,6-diamidino-2-phenylindole
(Vector Laboratories, Burlingame, CA, USA), sealed with clear nail
polish, and immediately studied. Controls were performed with the
elimination of the primary antibody and showed no staining.
IaI immunolocalization. Slides were initially processed as
described for osteopontin. Dr Jan Enghild (University of Aarhus)
supplied us with four different rabbit polyclonal antibodies
(bikunin, H1, H1 and H2, and H3) representing some of the
protein chains of the IaI inhibitor for these studies. These primary
antibodies were diluted 1:100 for bikunin, 1:200 for H1, 1:200 for
H1 and H2, and 1:350 for H3 and incubated overnight at room
temperature. The secondary antibody for each of these antibodies
was goat-anti-rabbit-fluorescein isothiocyanate IgG (Jackson Im-
munoResearch), and it was diluted at 1:100 in 2% normal goat
serum/PBS, which was incubated on the slide at room temperature
for 1 h. The slides were then processed as for osteopontin above.
Controls showed no staining as above.
Colocalization of osteopontin and bikunin. In a separate
study, osteopontin antibody (LFMb-14 from Dr Larry Fisher, NIH)
and bikunin antibody were colocalized on the same section.
Osteopontin antibody was used at a 1:200 dilution, whereas bikunin
antibody was used at a 1:100 dilution and each were incubated
overnight at room temperature. The secondary antibody for
osteopontin was goat-anti-mouse-rhodamine IgG and goat-anti-
rabbit-fluorescein isothiocyanate IgG for bikunin. Each was used at
a dilution of 1:100 in 2% normal goat serum/PBS, which was
incubated on the slide at room temperature for 1 h.
Colocaliztion of osteopontin and H3. In a separate study,
osteopontin antibody (LFMb-14) and H3 antibody were colocalized
on the same section. Osteopontin antibody was used at a 1:250
dilution while H3 antibody was used at a 1:350 dilution and each
were incubated overnight at room temperature. The secondary
antibody for osteopontin was goat-anti-mouse-rhodamine IgG and
goat-anti-rabbit-fluorescein isothiocyanate IgG for H3. Each was
used at a dilution of 1:100 in 2% normal goat serum/PBS, which was
incubated on the slide at room temperature for one hour.
Hyaluronan-binding protein. Hyaluronan was localized using
biotinylated hyaluronic acid-binding protein (HABP) (Associates of
Cape Cod Inc., East Fairmouth, MA, USA) in both routine
formalin-fixed biopsy tissue and the 10% formalin in 70% ethanol
and 5% glacial acetic acid-fixed biopsy. In addition, a fresh biopsy of
human skin was fixed in 10% formalin in 70% ethanol and 5%
glacial acetic acid and served as a control tissue for hyaluronan
localization. All slides were initially processed as described for
osteopontin but blocked for nonspecific protein binding using 3%
Blotto plus 0.1% Tween 20 at room temperature for 1 h.
Subsequently, sections were exposed to HABP at a dilution of
1:150 on the slide at room temperature overnight. Reactivity was
detected with the ELITE ABC kit (Vector Laboratories) and
3,3-diaminobenzidine tetrahydrochloride) in Tris-HCl buffer as
the chromogen. All sections were covered with 3,3-diaminobenzi-
dine tetrahydrochloride solution (0.05 mol l1 Tris–HCl, 0.001%
hydrogen peroxide, and 0.10% 3,3-diaminobenzidine tetrahy-
drochloride) and incubated for approximately 5 min. Finally, each
slide was rinsed well with buffer and lightly counterstained with
methyl green. Controls were performed with the elimination of the
primary antibody and showed no staining.
TEM
A separate set of 5-mm papillary samples was taken from four
of the original 15 ICSF patients during surgery, fixed in fresh
5% paraformaldehyde in phosphate buffer (pH 7.4), and divided in
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1-mm blocks for bikunin, H1, H1 and H2, and H3 immunoelectron
microscopic analysis. An additional papillary biopsy from one of the
non-stone formers from our original study was examined.
Tissue blocks used for routine immunoelectron microscopic
analysis were processed as described previously.38 Tissue sections
were incubated overnight at 41C with H3 antibody diluted at 1:50,
bikunin antibody diluted at 1:100, and H1 and H1 and H2 antibody
diluted at 1:100 in incubation buffer (0.1% bovine serum albumin
and 0.05% Tween 20 in PBS). Each grid was rinsed in three changes
of the incubation buffer before incubation in secondary antibody.
The secondary antibody was goat anti-rabbit conjugated with 10 nm
gold particles or to a universal secondary antibody protein A
(Electron Microscopy Science, Ft. Washington, PA, USA). Exposure
to the secondary antibody was followed by post fixation in 2.5%
glutaraldehyde in 0.1 M phosphate buffer and six rinses in distilled
water. For contrast, grids were stained with uranyl acetate and lead
citrate, rinsed, and air dried in Petri dishes lined with filter paper.
One original papillary biopsy sample was prepared for ultracryo
TEM to prepare frozen ultrathin sections for immunoelectron
analysis. This technique has the advantage of the sections never
being exposed to an aqueous solution thus preventing potential
movement of the marker being investigated. Initially, the sample was
placed in 0.1 M cacodylate buffer over the weekend to wash out the
PBS from the tissue. Subsequently, the tissue was rinsed three times
for 1 h each in a solution of 0.1 M cacodylate plus 3.5% sucrose at
41C, quenched in 50 mM ammonium chloride in cacodylate/sucrose
buffer for 1 h at 41C, rinsed twice for 1 h each in 0.1 M maleate buffer
plus 3.5% sucrose at pH 6.0, and rinsed overnight in maleate/
sucrose buffer at 41C. The tissue was post-fixed with 2% uranyl
acetate in maleate/sucrose buffer at pH 6.0 for 2 h at 41C followed by
another 1-h rinse in the maleate/sucrose buffer at 41C and a graded
dehydration set of acetone at 201C. The tissue is then infiltrated
with LR gold overnight at 201C Ultrathin sections were cut using a
Leica Ultracut microtome with a cryostage. Sections were picked up
with a loop and a drop of methylcellulose was placed on a 200-mesh
nickel grid and allowed to air dry overnight at 41C before staining.
Subsequently, the sections were prepared for immunolabeling by
first quenching the tissue with a solution of 20 mM tris-buffered
saline (TBS) (150 mM NaCl) plus 50 mM glycine for 15 min at
room temperature followed by a blocking step using TBS with 5%
bovine serum albumin plus 0.1% coldwater fish skin (CWFS) for
20 min at room temperature. Each grid was then exposed to the
primary antibody in a humid chamber overnight at 41C. Bikunin
antibody was used at a dilution of 1:100 and H3 antibody at a
dilution of 1:10. The grids were rinsed in an incubation buffer
six times for 5 min each followed by exposure to protein A
(the secondary antibody) at 10 nM and a dilution of 1:40 in the
incubation buffer for 2 h at room temperature. Next the grids were
rinsed with three drops of TBS incubation buffer for 5 min each,
post-fixed with a solution of 1% glutaraldehyde in TBS for 5 min at
room temperature, rinsed three times with TBS for 2 min each and
stained with uranyl acetate.
All grids used for routine TEM and immunoelectron analysis
were viewed with an FEI G2 Tecnai 12 BioTwin transmission
electron microscope (FEI, Hillsboro, OR, USA), equipped with an
AMT Corp, XR-60 Digital CCD system.
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